The launch of a new registry to evaluate thrombectomy for pulmonary embolism is significant as it may reshape clinical guidelines and influence treatment adoption. Monitoring the outcomes will be crucial for understanding the procedure's viability and its competitive landscape against existing treatment modalities. Regulatory context from MHRA (Pioneering AI health innovations regulatory sandbox launched) supports the near-term read. Assessment grounded in 10 ranked evidence items (1 high-relevance).